Compare CJET & XBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CJET | XBIO |
|---|---|---|
| Founded | 2009 | N/A |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Auto Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.0M | 5.9M |
| IPO Year | N/A | N/A |
| Metric | CJET | XBIO |
|---|---|---|
| Price | $0.87 | $2.41 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 3.0M | 47.5K |
| Earning Date | 03-26-2026 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $4,107,000.00 | $2,858,935.00 |
| Revenue This Year | N/A | $1.99 |
| Revenue Next Year | N/A | $20.00 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 13.30 |
| 52 Week Low | $0.82 | $2.20 |
| 52 Week High | $299.00 | $13.93 |
| Indicator | CJET | XBIO |
|---|---|---|
| Relative Strength Index (RSI) | 38.48 | 40.78 |
| Support Level | $0.82 | $2.31 |
| Resistance Level | $1.28 | $2.64 |
| Average True Range (ATR) | 0.29 | 0.18 |
| MACD | -0.14 | 0.05 |
| Stochastic Oscillator | 2.07 | 31.65 |
Chijet Motor Company Inc is engaged in the development, manufacture, sales, and service of new energy vehicles (NEV), hybrid vehicles and traditional fuel vehicles in China. New energy vehicles refer to plug-in electric vehicles, including battery electric vehicles, plug-in hybrid (PHEV) electric vehicles, and fuel cell electric vehicles. Its passenger vehicles include small cars, sedans, and sports utility vehicles, or SUVs, and commercial vehicles include light trucks and vans. The company generates all of its revenue from PRC.
Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers. The company's DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is also focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and other locally metastatic solid tumors.